Alithea Bio: Featured in smartXhealth Startup Spotlight

Advancing Immunopeptidomics: Highlights from the Boston Expert Session

Real-Time Immunopeptidomics: Accelerating Target Validation with HLA-Compass

4,000 Strong: Celebrating Our Growing Community in Precision Immunotherapy

Beyond Cancer: How Immunopeptidomics is Unlocking the Next Frontier in HIV Cure Research

Bridging the Gap Between AI and Immunity: Alithea Bio Named UN AI for Good Finalist

Advancing Immunopeptidomics: Meet the Experts Behind the Conference

Alithea Bio at IO360° 2026: Showcasing Novel Immunopeptidomics Technologies

The Future of Neoantigen Discovery: Trends and Challenges

Off-Target Toxicity in Immunotherapy: Identification and Mitigation Strategies

Mass Spectrometry vs. NGS for HLA Peptide Analysis:Pros and Cons

HLA Peptide Characterization: The Key to Safer TCR Therapies

How Immunopeptidomics is Revolutionizing Cancer Immunotherapy

The Complete Guide to Immunopeptidomics: From Workflow Optimization to Biologics Testing

Breaking the Silence: Alithea Bio and CHOP Unveil “HLA-Shuttle” to Target Immunologically Cold Tumors

Is Multiantigen T-Cell Therapy the Future of Pancreatic Cancer Care?

The Double Agent: Soluble HLA as a Master Regulator of Immunity

The Hidden Repertoire: Neoself-Antigens in Lupus and Cancer

Breaking Tolerance: Can We Successfully Target Self-Antigens Without Unmanageable Toxicity?

Personalized TCR Therapy: From “Impossible” to Proven in Nature Medicine

The Trap in the Microenvironment: Why TAMs are the Real Drivers of T-Cell Exhaustion

Engineering Out the Immune Response: How Immunopeptidomics is De-Risking AAV Gene Therapy

From Heatmap to Safety Assessment: Rapid Off-Target Screening in HLA-Compass

Is HLA Allele Loss Overstated? Insights from 80k Patients

The Hierarchy of Healing: How mRNA Vaccines Shape T-Cell Fate

Heart of the Matter: Solving the Titin Toxicity Challenge in HLA-A*02:01 Immunotherapy

Alithea Bio Launches HLA-Compass Binding Prediction

HLA Profiling: Enhancing Precision in Immunopeptidomics and Immunotherapy

Immunopeptidomics Unlocks New Paths for mRNA Vaccine Design

Alithea Bio to Participate at BIO-Europe 2025

Alithea Bio at CHI’s 17th Annual Immunogenicity & Bioassay Summit – Alexandria, VA, Oct 7–10, 2025

Alithea Bio at the Festival of Biologics 2025

🏆 Alithea Bio Wins Freiburger Innovationspreis 2025 for HLA‑Compass

Alithea Bio at #BayOConnect2025: Let’s Shape the Future of Immunotherapy

Alithea Bio attending the 8th International Neoantigen Summit

Webinar Recap: How HLA-Compass is Transforming Immunopeptidomics for Safer, Faster Immunotherapy

Alithea Bio zu Gast bei der Meisterklasse von Gründermotor

Die Investment Readiness Meisterklasse ist ein 5-wöchiges Accelerator-Programm des Gründermotors. Das Ziel ist Startups, die in den nächsten 3-6 Monaten…

13.02.2024 PRESS RELEASE

Freiburg/Oxford: Alithea Bio is thrilled to announce a strategic collaboration with Exogene, co-funded by the German ZIM and Innovate UK, combining our expertise to…